Therefore, the aim of this study is to screen for potential repurposable FDA-approved drugs against HDAC6 (braking the cancer progression) and VISTA (removing the imposed immunosuppression) as a novel dual therapeutic strategy for cancer treatment. Here, HDAC6 is linked to cancer.